Buy Full Version
"Plasma Fractionation Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Plasma Fractionation Market by Product (Albumin, Immunoglobulins, and Coagulation Factor VIII), Application (Neurology, Hematology, Immunology, Critical Care and Others), End User (Hospitals, and Research Laboratories): Global Opportunity Analysis and Industry Forecast, 2018–2028

Healthcare	A00943	Pages: 205	Nov 2019 \| 1780 Views
Author(s) : Sanjivan Gill , Onkar Sumant	Tables: 131	Charts: 33	Formats*:

Plasma Fractionation Market Outlook-2028

The global plasma fractionation market was valued at $16,823 million in 2018, and is expected to reach $30,536 million by 2028, registering a CAGR of 6.1% from 2019 to 2028.

Fractionation is a process which is carried out to separate certain quantity of mixture. Furthermore, plasma is the fluid component of the blood, which is fractionated to obtain different plasma derivatives such as albumin, immunoglobulins, and others. These derived plasma products have therapeutic effects and are employed in the treatment of various blood plasma related disorders. For instance, coagulation factor VIII is a plasma derivative, which is used for the treatment and prophylaxis of hemophilia. Furthermore, it is also employed to stop excessive blood loss during surgical procedures. Similarly, immunoglobulins are employed in the treatment of primary and secondary immune deficiencies.

Get more information on this report : Request Sample Pages

The factors that boost the growth of the plasma fractionation market include surge in geriatric population across the globe, which is predisposed to various rare diseases that require the use of plasma derivatives. Moreover, rise in use of immunoglobulins in areas of medicine worldwide also fuel the growth of the plasma fractionation market. Furthermore, surge in plasma collection centers worldwide is another major factor that contributes toward the growth of the market.

Plasma Fractionation Market Segmentation

The global plasma fractionation market size is studied on the basis of product, application, end user, and country. On the basis of product, the market is segmented into the market is divided into albumin, immunoglobulins, and coagulation factor VIII. Moreover, immunoglobulins are further divided into subcutaneous immunoglobulin (SCIG) and coagulation factor VIII. By application, the market is classified into neurology, hematology, immunology, critical care, and others. On the basis of end user, it is categorized into hospitals and clinical research laboratories. By country, it is analyzed across Russia, Kazakhstan, Indonesia, China (Including Taiwan), India, Saudi Arabia, Egypt, Vietnam, Argentina, Thailand, and Nigeria.

Segment Review

By product, the immunoglobulin segment occupied the largest plasma fractionation market share in 2018. Furthermore, it is also expected to exhibit the fastest growth rate during the forecast period. The growth of this segment is attributable to the diversified use of immunoglobulin in various disorders such as primary and secondary immune deficiencies, autoimmune diseases, and inflammatory diseases. Furthermore, surge in research related to immunology across the globe is another factor that contributes toward the growth of the immunoglobulin market.

Plasma Fractionation Market
By Product

Immunoglobulin segment holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By application, neurology acquired the largest plasma fractionation market share and is also the fastest growing segment during the forecast period. This is attributable to the surge in the neurological disorders that require plasma fractionation products for treatment. Furthermore, surge in the adoption of plasma fractionation products in the field of neurology is another major factor that contributes toward the growth of the market.

Plasma Fractionation Market
By Application

Neurology is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

On the basis of country, China (including Taiwan) is expected to grow at the fastest growth rate during the forecast period. The growth is attributable to presence of large population which has a huge demand for plasma fractionation products. Furthermore, surge in various medical conditions that require the use of plasma fractionation products is another major factor that contributes to the growth of the market.

Plasma Fractionation Market
By Country

2028

Rest of the World

Russia

Kazakhstan

Indonesia

China (Including Taiwan)

India

Saudi Arabia

Egypt

Vietnam

Argentina

Thailand

Nigeria

China (Including Taiwan) would exhibit the highest CAGR of 7.4% during 2019-2028.

Get more information on this report : Request Sample Pages

The global plasma fractionation market is highly competitive and the prominent players in the market have adopted various strategies for garnering maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Grifols SA, Baxter International Inc., CSL LTD., Bio Product Laboratory, Octapharma AG, Sanquin, Laboratoire Franais Du Fractionnement Et Des, Kedrion, Biotest, and Takeda Pharmaceuticals.

Key Benefits for Plasma Fractionation Market :

This report entails a detailed quantitative analysis along with the current global plasma fractionation market trends from 2019 to 2028 to identify the prevailing opportunities along with the strategic assessment.
The plasma fractionation market forecast is studied from 2019 to 2028.
The market size and estimations are based on a comprehensive analysis of key developments in the plasma fractionation industry.
A qualitative analysis based on innovative products facilitates strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Plasma Fractionation Market Segments:

By Product

Albumin
Immunoglobulins
Subcutaneous Immunoglobulin (SCIG)
Intravenous Immunoglobulin (IVIG)
Coagulation Factor

By Application

Neurology
Hematology
Immunology
Critical Care
Others

By End User

Hospitals
Clinical Research Laboratories

By Country

Russia
Kazakhstan
Indonesia
China (Including Taiwan)
India
Saudi Arabia
Egypt
Vietnam
Argentina
Thailand
Nigeria
Rest of the World

CHAPTER 1: INTRODUCTION

1.1.   Report description
1.2.   Key benefits for stakeholders
1.3.   Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1.   Secondary research
1.4.2.   Primary research
1.4.3.   Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Porter's five forces analysis

3.3.1.   Bargaining power of buyers
3.3.2.   Bargaining power of suppliers
3.3.3.   Thereat of new entrants
3.3.4.   Threat of substitutes
3.3.5.   Intensity of competitive rivalry

3.4. Top player positioning, 2018
3.5. Market dynamics

3.5.1. Drivers

3.5.1.1.   Surge in geriatric population across the globe coupled with rise in prevalence of rare diseases
3.5.1.2.   Rise in use of immunoglobulins in areas of medicine
3.5.1.3.   Increase in number of plasma collection centers across the globe

3.5.2. Restraint

3.5.2.1. High cost of plasma derived products

3.5.3. Opportunity

3.5.3.1. High growth potential in emerging economies

3.5.4. Impact Analysis

CHAPTER 4: PLASMA FRACTIONATION MARKET, BY PRODUCT

4.1. Overview

4.1.1. Market size and forecast

4.2. Albumin

4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast, by country

4.3. Immunoglobulins

4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast, by type

4.3.2.1. Subcutaneous Immunoglobulin

4.3.2.1.1. Market size and forecast

4.3.2.2. Intravenous Immunoglobulin

4.3.2.2.1. Market size and forecast

4.3.3. Market size and forecast, by country

4.4. Coagulation factor VIII

4.4.1. Key market trends and growth opportunities
4.4.2. Market size and forecast, by country

CHAPTER 5: PLASMA FRACTIONATION MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Neurology

5.2.1. Market size and forecast, by region

5.3. Hematology

5.3.1. Market size and forecast, by region

5.4. Immunology

5.4.1. Market size and forecast, by region

5.5. Critical care

5.5.1. Market size and forecast, by region

5.6. Others

5.6.1. Market size and forecast, by region

CHAPTER 6: PLASMA FRACTIONATION MARKET, BY END USER

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals

6.2.1. Market size and forecast, by region

6.3. Clinical research laboratories

6.3.1. Market size and forecast, by region

CHAPTER 7: PLASMA FRACTIONATION MARKET, BY COUNTRY

7.1. Overview

7.1.1. Market size and forecast

7.2. Russia

7.2.1.   Key market trends and growth opportunities
7.2.2.   Market size and forecast, by product
7.2.3.   Market size and forecast, by application
7.2.4.   Market size and forecast, by end user

7.3. Kazakhstan

7.3.1.   Key market trends and growth opportunities
7.3.2.   Market size and forecast, by product
7.3.3.   Market size and forecast, by application
7.3.4.   Market size and forecast, by end user

7.4. Indonesia

7.4.1.   Key market trends and growth opportunities
7.4.2.   Market size and forecast, by product
7.4.3.   Market size and forecast, by application
7.4.4.   Market size and forecast, by end user

7.5. China (Including Taiwan)

7.5.1.   Key market trends and growth opportunities
7.5.2.   Market size and forecast, by product
7.5.3.   Market size and forecast, by application
7.5.4.   Market size and forecast, by end user

7.6. India

7.6.1.   Key market trends and growth opportunities
7.6.2.   Market size and forecast, by product
7.6.3.   Market size and forecast, by application
7.6.4.   Market size and forecast, by end user

7.7. Saudi Arabia

7.7.1.   Key market trends and growth opportunities
7.7.2.   Market size and forecast, by product
7.7.3.   Market size and forecast, by application
7.7.4.   Market size and forecast, by end user

7.8. Egypt

7.8.1.   Key market trends and growth opportunities
7.8.2.   Market size and forecast, by product
7.8.3.   Market size and forecast, by application
7.8.4.   Market size and forecast, by end user

7.9. Vietnam

7.9.1.   Key market trends and growth opportunities
7.9.2.   Market size and forecast, by product
7.9.3.   Market size and forecast, by application
7.9.4.   Market size and forecast, by end user

7.10. Argentina

7.10.1.   Key market trends and growth opportunities
7.10.2.   Market size and forecast, by product
7.10.3.   Market size and forecast, by application
7.10.4.   Market size and forecast, by end user

7.11. Thailand

7.11.1.   Key market trends and growth opportunities
7.11.2.   Market size and forecast, by product
7.11.3.   Market size and forecast, by application
7.11.4.   Market size and forecast, by end user

7.12. Nigeria

7.12.1.   Key market trends and growth opportunities
7.12.2.   Market size and forecast, by product
7.12.3.   Market size and forecast, by application
7.12.4.   Market size and forecast, by end user

7.13. Rest of the World

7.13.1.   Key market trends and growth opportunities
7.13.2.   Market size and forecast, by product
7.13.3.   Market size and forecast, by application
7.13.4.   Market size and forecast, by end user

CHAPTER 8: COMPANY PROFILES

8.1. BAXTER INTERNATIONAL INC.

8.1.1.   Company overview
8.1.2.   Company snapshot
8.1.3.   Operating business segments
8.1.4.   Product portfolio
8.1.5.   Business performance

8.2. BIO PRODUCTS LABORATORY

8.2.1.   Company overview
8.2.2.   Company snapshot
8.2.3.   Operating business segments
8.2.4.   Product portfolio

8.3. BIOTEST AG

8.3.1.   Company overview
8.3.2.   Company snapshot
8.3.3.   Operating business segments
8.3.4.   Product portfolio
8.3.5.   Business performance
8.3.6.   Key strategic moves and developments

8.4. CSL LTD.

8.4.1.   Company overview
8.4.2.   Company snapshot
8.4.3.   Operating business segments
8.4.4.   Product portfolio
8.4.5.   Business performance

8.5. GRIFOLS SA

8.5.1.   Company overview
8.5.2.   Company snapshot
8.5.3.   Operating business segments
8.5.4.   Product portfolio
8.5.5.   Business performance

8.6. KEDRION BIOPHARMA

8.6.1.   Company overview
8.6.2.   Company snapshot
8.6.3.   Operating business segments
8.6.4.   Product portfolio
8.6.5.   Business performance

8.7. LFB S. A

8.7.1.   Company overview
8.7.2.   Company snapshot
8.7.3.   Operating business segments
8.7.4.   Product portfolio
8.7.5.   Business performance

8.8. OCTAPHARMA

8.8.1.   Company overview
8.8.2.   Company snapshot
8.8.3.   Operating business segments
8.8.4.   Product portfolio

8.9. SANQUIN BLOOD SUPPLY FOUNDATION

8.9.1.   Company overview
8.9.2.   Company snapshot
8.9.3.   Operating business segments
8.9.4.   Product portfolio
8.9.5.   Business performance

8.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED

8.10.1.   Company overview
8.10.2.   Company snapshot
8.10.3.   Operating business segments
8.10.4.   Product portfolio
8.10.5.   Business performance
8.10.6.   Key strategic moves and developments

LIST OF TABLES

TABLE 01.   GLOBAL PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 ($MILLION)
TABLE 02.   GLOBAL PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 (METRIC TONS)
TABLE 03.   PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2016–2028 ($MILLION)
TABLE 04.   PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2016–2028 (METRIC TONS)
TABLE 05.   PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2016–2028 ($MILLION)
TABLE 06.   PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2016–2028 ($MILLION)
TABLE 07.   PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2016–2028 ($MILLION)
TABLE 08.   PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2016–2028 (METRIC TONS)
TABLE 09.   PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII, BY COUNTRY, 2016–2028 ($MILLION)
TABLE 10.   PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII, BY COUNTRY, 2016–2028 (MILLION INTERNATIONAL UNIT)
TABLE 11.   GLOBAL PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 ($MILLION)
TABLE 12.   GLOBAL PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 (METRIC TONS)
TABLE 13.   PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2016–2028 ($MILLION)
TABLE 14.   PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2016–2028 (METRIC TONS)
TABLE 15.   PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2016–2028 ($MILLION)
TABLE 16.   PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2016–2028 (METRIC TONS)
TABLE 17.   PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2016–2028 ($MILLION)
TABLE 18.   PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2016–2028 (METRIC TONS)
TABLE 19.   PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2016–2028 ($MILLION)
TABLE 20.   PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2016–2028 (METRIC TONS)
TABLE 21.   PLASMA FRACTIONATION MARKET FOR OTHERS, BY COUNTRY, 2016–2028 ($MILLION)
TABLE 22.   PLASMA FRACTIONATION MARKET FOR OTHERS, BY COUNTRY, 2016–2028 (METRIC TONS)
TABLE 23.   GLOBAL PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 ($MILLION)
TABLE 24.   GLOBAL PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 (METRIC TONS )
TABLE 25.   PLASMA FRACTIONATION MARKET FOR HOSPITALS, BY COUNTRY, 2016–2028 ($MILLION)
TABLE 26.   PLASMA FRACTIONATION MARKET FOR HOSPITALS, BY COUNTRY, 2016–2028 (METRIC TONS )
TABLE 27.   PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2016–2028 ($MILLION)
TABLE 28.   PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2016–2028 (METRIC TONS )
TABLE 29.   GLOBAL PLASMA FRACTIONATION MARKET, BY COUNTRY, 2016–2028 ($MILLION)
TABLE 30.   GLOBAL PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 (METRIC TONS)
TABLE 31.   RUSSIA PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 ($MILLION)
TABLE 32.   RUSSIA PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 (METRIC TONS)
TABLE 33.   RUSSIA PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 ($MILLION)
TABLE 34.   RUSSIA PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 (METRIC TONS)
TABLE 35.   RUSSIA PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 ($MILLION)
TABLE 36.   RUSSIA PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 (METRIC TONS)
TABLE 37.   KAZAKHSTAN PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 ($MILLION)
TABLE 38.   KAZAKHSTAN PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 (METRIC TONS)
TABLE 39.   KAZAKHSTAN PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 ($MILLION)
TABLE 40.   KAZAKHSTAN PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 (METRIC TONS)
TABLE 41.   KAZAKHSTAN PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 ($MILLION)
TABLE 42.   KAZAKHSTAN PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 (METRIC TONS)
TABLE 43.   INDONESIA PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 ($MILLION)
TABLE 44.   INDONESIA PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 (METRIC TONS)
TABLE 45.   INDONESIA PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 ($MILLION)
TABLE 46.   INDONESIA PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 (METRIC TONS)
TABLE 47.   INDONESIA PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 ($MILLION)
TABLE 48.   INDONESIA PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 (METRIC TONS)
TABLE 49.   CHINA PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 ($MILLION)
TABLE 50.   CHINA PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 (METRIC TONS)
TABLE 51.   CHINA PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 ($MILLION)
TABLE 52.   CHINA PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 (METRIC TONS)
TABLE 53.   CHINA PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 ($MILLION)
TABLE 54.   CHINA PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 (METRIC TONS)
TABLE 55.   INDIA PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 ($MILLION)
TABLE 56.   INDIA PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 (METRIC TONS)
TABLE 57.   INDIA PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 ($MILLION)
TABLE 58.   INDIA PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 (METRIC TONS)
TABLE 59.   INDIA PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 ($MILLION)
TABLE 60.   INDIA PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 (METRIC TONS)
TABLE 61.   SAUDI ARABIA PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 ($MILLION)
TABLE 62.   SAUDI ARABIA PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 (METRIC TONS)
TABLE 63.   SAUDI ARABIA PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 ($MILLION)
TABLE 64.   SAUDI ARABIA PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 (METRIC TONS)
TABLE 65.   SAUDI ARABIA PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 ($MILLION)
TABLE 66.   SAUDI ARABIA PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 (METRIC TONS)
TABLE 67.   EGYPT PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 ($MILLION)
TABLE 68.   EGYPT PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 (METRIC TONS)
TABLE 69.   EGYPT PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 ($MILLION)
TABLE 70.   EGYPT PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 (METRIC TONS)
TABLE 71.   EGYPT PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 ($MILLION)
TABLE 72.   EGYPT PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 (METRIC TONS)
TABLE 73.   VIETNAM PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 ($MILLION)
TABLE 74.   VIETNAM PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 (METRIC TONS)
TABLE 75.   VIETNAM PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 ($MILLION)
TABLE 76.   VIETNAM PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 (METRIC TONS)
TABLE 77.   VIETNAM PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 ($MILLION)
TABLE 78.   VIETNAM PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 (METRIC TONS)
TABLE 79.   ARGENTINA PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 ($MILLION)
TABLE 80.   ARGENTINA PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 (METRIC TONS)
TABLE 81.   ARGENTINA PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 ($MILLION)
TABLE 82.   ARGENTINA PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 (METRIC TONS)
TABLE 83.   ARGENTINA PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 ($MILLION)
TABLE 84.   ARGENTINA PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 (METRIC TONS)
TABLE 85.   THAILAND PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 ($MILLION)
TABLE 86.   THAILAND PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 (METRIC TONS)
TABLE 87.   THAILAND PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 ($MILLION)
TABLE 88.   THAILAND PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 (METRIC TONS)
TABLE 89.   THAILAND PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 ($MILLION)
TABLE 90.   THAILAND PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 (METRIC TONS)
TABLE 91.   NIGERIA PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 ($MILLION)
TABLE 92.   NIGERIA PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 (METRIC TONS)
TABLE 93.   NIGERIA PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 ($MILLION)
TABLE 94.   NIGERIA PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 (METRIC TONS)
TABLE 95.   NIGERIA PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 ($MILLION)
TABLE 96.   NIGERIA PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 (METRIC TONS)
TABLE 97.   REST OF THE WORLD PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 ($MILLION)
TABLE 98.   REST OF THE WORLD PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2028 (METRIC TONS)
TABLE 99.   REST OF THE WORLD PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 ($MILLION)
TABLE 100.   REST OF THE WORLD PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2028 (METRIC TONS)
TABLE 101.   REST OF THE WORLD PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 ($MILLION)
TABLE 102.   REST OF THE WORLD PLASMA FRACTIONATION MARKET, BY END USER, 2016–2028 (METRIC TONS)
TABLE 103.   BAXTER: COMPANY SNAPSHOT
TABLE 104.   BAXTER: PRODUCT SEGMENT
TABLE 105.   BAXTER: PRODUCT PORTFOLIO
TABLE 106.   BIO PRODUCTS LABORATORY: COMPANY SNAPSHOT
TABLE 107.   BIO PRODUCTS LABORATORY: OPERATING SEGMENTS
TABLE 108.   BIO PRODUCTS LABORATORY: PRODUCT PORTFOLIO
TABLE 109.   BIOTEST AG: COMPANY SNAPSHOT
TABLE 110.   BIOTEST AG: OPERATING SEGMENTS
TABLE 111.   BIOTEST AG: PRODUCT PORTFOLIO
TABLE 112.   CSL LTD..: COMPANY SNAPSHOT
TABLE 113.   CSL LTD..: OPERATING SEGMENT
TABLE 114.   CSL LTD..: PRODUCT PORTFOLIO
TABLE 115.   GRIFOLS SA: COMPANY SNAPSHOT
TABLE 116.   GRIFOLS SA: OPERATING SEGMENTS
TABLE 117.   GRIFOLS SA: PRODUCT PORTFOLIO
TABLE 118.   KEDRION: COMPANY SNAPSHOT
TABLE 119.   KEDRION: OPERATING SEGMENTS
TABLE 120.   KEDRION: PRODUCT PORTFOLIO
TABLE 121.   LFB S.A: COMPANY SNAPSHOT
TABLE 122.   LFB S.A: OPERATING SEGMENTS
TABLE 123.   LFB S.A: PRODUCT PORTFOLIO
TABLE 124.   OCTAPHARMA: COMPANY SNAPSHOT
TABLE 125.   OCTAPHARMA: OPERATING SEGMENTS
TABLE 126.   OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 127.   SANQUIN BLOOD SUPPLY FOUNDATION: COMPANY SNAPSHOT
TABLE 128.   SANQUIN BLOOD SUPPLY FOUNDATION: OPERATING SEGMENTS
TABLE 129.   SANQUIN BLOOD SUPPLY FOUNDATION: PRODUCT PORTFOLIO
TABLE 130.   TAKEDA: COMPANY SNAPSHOT
TABLE 131.   TAKEDA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.   GLOBAL PLASMA FRACTIONATION MARKET SEGMENTATION
FIGURE 02.   TOP INVESTMENT POCKETS
FIGURE 03.   MODERATE BARGAINING POWER OF BUYERS
FIGURE 04.   LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05.   LOW THREAT OF NEW ENTRANTS
FIGURE 07.   MODERATE COMPETITIVE RIVALRY
FIGURE 08.   TOP PLAYER POSITIONING, 2018
FIGURE 09.   WORLD POPULATION AGED 65 AND OVER (%)
FIGURE 10.   IMPACT ANALYSES, PLASMA FRACTIONATION MARKET
FIGURE 11.   SUBCUTANEOUS IMMUNOGLOBULIN MARKET, 2016–2028 ($MILLION AND VOLUME)
FIGURE 12.   INTRAVENOUS IMMUNOGLOBULIN MARKET, 2016–2028 ($MILLION AND VOLUME)
FIGURE 13.   BAXTER: NET SALES, 2016–2018 ($MILLION)
FIGURE 14.   BAXTER: REVENUE SHARE BY SEGMENTS, 2018(%)
FIGURE 15.   BAXTER: REVENUE SHARE BY REGION 2018(%)
FIGURE 16.   BIOTEST AG: NET SALES, 2016–2018 ($MILLION)
FIGURE 17.   BIOTEST AG: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 18.   BIOTEST AG: REVENUE SHARE BY REGION, 2018(%)
FIGURE 19.   CSL LTD.: NET SALES, 2016–2018 ($MILLION)
FIGURE 20.   CSL LTD.: REVENUE SHARE BY SEGMENT, 2019(%)
FIGURE 21.   GRIFOLS SA: NET SALES, 2016–2018 ($MILLION)
FIGURE 22.   GRIFOLS SA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 23.   GRIFOLS SA: REVENUE SHARE BY REGION, 2018(%)
FIGURE 24.   KEDRION: NET SALES, 2016–2018 ($MILLION)
FIGURE 25.   KEDRION: REVENUE SHARE BY REGION, 2018(%)
FIGURE 26.   LFB S.A: NET SALES, 2016–2018 ($MILLION)
FIGURE 27.   LFB S.A: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 28.   SANQUIN BLOOD SUPPLY FOUNDATION: NET SALES, 2017–2018 ($MILLION)
FIGURE 29.   SANQUIN BLOOD SUPPLY FOUNDATION: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 30.   SANQUIN BLOOD SUPPLY FOUNDATION: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 31.   TAKEDA: NET SALES, 2017–2019 ($MILLION)
FIGURE 32.   TAKEDA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 33.   TAKEDA: REVENUE SHARE BY REGION, 2019 (%)

Plasma fractionation products are expected to witness high adoption in the near future, owing to increase in number of plasma collection centers. In addition, the market is exhibiting high growth rate, owing to surge in awareness about use of the plasma fractionation products in various medical aspects.

Moreover, surge in geriatric population across the globe which is predisposed to rare diseases that require plasma products for treatment also fuels the growth of the market. Asia-Pacific and LAMEA are expected to offer lucrative growth opportunities to the key players.

This is majorly attributed to factors such as improvement in healthcare facilities, rise in disposable income, and rapid improvement in economic conditions. However, high cost of plasma products hinders the growth of the plasma fractionation market. Plasma fractionation product manufacturers and distributors have focused on expanding their presence in the emerging economies to strengthen their foothold in the market.

Online Only ~~$3,456~~ $3,041 Data Pack/Excel ~~$3,840~~ $3,379 Single User License ~~$5,370~~ $4,296 Five User License ~~$6,450~~ $4,838 Enterprise User License ~~$8,995~~ $6,297

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com